DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS
Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.
1 . A balloon catheter comprising:
an elongated balloon comprising a first main section, a neck section, and a second main section.
2 . The balloon catheter of claim 1 , wherein the first main section and second main section have a main diameter when the balloon is inflated, and wherein the neck section comprises an inflated diameter that is smaller than the inflated main diameter of the first and second sections.
3 . The balloon catheter of claim 1 , wherein the neck section comprises a reinforcing material around a circumference of the neck section to reduce compliance during inflation.
4 . The balloon catheter of claim 3 , wherein the reinforcing material comprises a suture, monofilament, or multifilament, wherein the reinforcing material comprises nylon, a polyamide, an aromatic polyamide, ultra high molecular weight polyethylene (UHMWPE), a polyester, an aromatic polyester, polyethylene terephthalate (PET), or a combination thereof.
5 . The balloon catheter of claim 1 , further comprising a coating layer overlying an exterior surface of the balloon.
6 . The balloon catheter of claim 5 , wherein the coating layer comprises one or more water-soluble additives and a therapeutic agent.
7 . The balloon catheter of claim 6 , wherein the therapeutic agent comprises paclitaxel, a paclitaxel analogue, docetaxel, a docetaxel analogue, taxol, a taxol analogue, rapamycin, a rapamycin analogue, sirolimus, a sirolimus analogue, everolimus, an everolimus analogue, tacrolimus, a tacrolimus analogue, mammalian target of rapamycin (mTOR) inhibitors, an mTOR inhibitor analogue, or a combination thereof.
8 . The balloon catheter of claim 1 , wherein the first main section and second main section have a main diameter when the balloon is inflated, and wherein the main diameter is at least 13 mm, or at least 15 mm, or at least 20 mm, or at least 30 mm, or at least 35 mm.
9 . The balloon catheter of claim 1 , further comprising a catheter shaft comprising an interior lumen for delivery of inflation fluid to the balloon interior.
10 . The balloon catheter of claim 1 , wherein the balloon comprises multiple main sections separated by multiple neck sections.
11 . A method of treating a target site in a body lumen, comprising:
inserting a balloon catheter into the target site in the body lumen, the balloon catheter comprising an elongated balloon comprising a first main section, a neck section, and a second main section;
inflating the balloon catheter.
12 . The method of claim 11 , wherein the target site comprises a vascular lumen, a nonvascular lumen, a coronary artery, a peripheral artery, a urethra, a ureter, a prostatic urethra, an esophagus, a biliary tract, a stomach, a small intestine, a duodenum, a jejunum, an ileum, a colon, a rectum, a large intestine, a sinus, or an airway.
13 . The method of claim 11 , wherein the balloon catheter comprises a coating layer overlying an exterior surface of the balloon.
14 . The method of claim 13 , wherein the coating layer comprises one or more water-soluble additives and a therapeutic agent.
15 . The method of claim 11 , further comprising:
deflating the balloon catheter; and
withdrawing the balloon catheter from the body lumen.
16 . The method of claim 11 , wherein the body lumen comprises a scope, and wherein the method comprises positioning the balloon catheter and the scope side-by-side or loading the balloon catheter into the scope.
17 . The method of claim 11 , wherein the balloon catheter has a ratio of inflated balloon diameter to normative body lumen diameter at the target site of 1.31 to 10.
18 . The method of claim 11 , wherein inflating comprises inflating the first main section, the neck section, and the second main section simultaneously via a single inflation lumen.
19 . The method of claim 11 , wherein the method comprises treating benign prostatic hyperplasia.
20 . The method of claim 11 , wherein the method increases Qmax to a minimum of 15 mL/s or decreases International Prostate Symptom Score (IPSS) to 14 or less.